There is a pressing medical need to develop innovative therapeutic approaches to improve the outcome and survival of pancreatic cancer patients. While the development of immunotherapies has represented a breakthrough that has revolutionized oncology treatments, they have proven non-efficacious in pancreatic tumors since they are considered non-immunogenic tumors. Thus, turning pancreatic tumors into immunogenic tumors could open new treatment avenues making them candidates for immunotherapies. This can be achieved by integrating techniques from two Key Enabling Technologies (KETs), nanotechnology and photonics.PANIPAC proposes the development of photoactivable nanoemulsions made of bioactive sphingolipids which, via a dual mechanism of action, should increase the immunogenicity of pancreatic tumours. This goal can be achieved by i) reverting the tolerogenic/immunosuppressive microenvironment of pancreatic cancer by modulating the phenotype of tumor associated immune cells (e.g. tumor-associated macrophages), and ii) mediating the infiltration of T effector lymphocytes (Teff), to reset the immunogenicity of pancreatic tumors, and make them candidates for the development of combinatory therapies with checkpoint inhibitors and/or other immune therapies such as bispecific antibodies. If successful, the
cáncer pancreático
nanotecnología
fotónica
inmunoterapia
inmunomodulación
microambiente tumoral
Acción Estratégica en Salud (AES)
01/01/2019 - 31/12/2021
LOPEZ LOPEZ, RAFAEL
CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. (CIBER)
INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA (IDIS)
Galicia
Coruña, A
169,703 €